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Mapping of lymphatic filariasis (LF) caused by Wuchereria bancrofti largely relies on the
detection of circulating antigen using ICT cards. Several studies have recently shown that
this test can be cross-reactive with sera of subjects heavily infected with Loa loa and thus
mapping results in loiasis endemic areas may be inaccurate.
Methodology/Principal findings
In order to develop an LF mapping strategy for areas with high loiasis prevalence, we col-
lected day blood samples from 5,001 subjects residing in 50 villages that make up 6 health
districts throughout Cameroon. Antigen testing using Filarial Test Strip (FTS, a novel plat-
form that uses the same reagents as ICT) revealed an overall positivity rate of 1.1% and L.
loa microfilaria (Mf) rates of up to 46%. Among the subjects with 0 to 8,000 Mf/ml in day
blood, only 0.4% were FTS positive, while 22.2% of subjects with >8,000 Mf/ml were FTS
positive. A Mf density of >8,200 Mf/ml was determined as the cut point at which positive FTS
results should be excluded from the analysis. No FTS positive samples were also positive
for W. bancrofti antibodies as measured by two different point of care tests that use the
Wb123 antigen not found in L. loa. Night blood examination of the FTS positive subjects
showed a high prevalence of L. loa Mf with densities up to 12,710 Mf/ml. No W. bancrofti Mf
were identified, as confirmed by qPCR. Our results show that high loads of L. loa Mf in day
blood are a reliable indicator of FTS positivity, and Wb123 rapid test proved to be relatively
specific.
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Conclusions/Significance
Our study provides a simple day blood-based algorithm for LF mapping in loiasis areas. The
results indicate that many districts that were formerly classified as endemic for LF in Camer-
oon are non-endemic and do not require mass drug administration for elimination of LF.
Author summary
High prevalence of loiasis can confound the mapping efforts for lymphatic filariasis (LF)
that use tests for circulating filarial antigen. In order to develop a LF mapping strategy for
loiasis endemic areas, we screened day blood samples from 5,001 subjects residing in 50
villages in 6 health districts throughout Cameroon. Circulating filarial antigen (FTS) rates
varied from 0.3 to 2.2% between health districts while L. loa microfilaria (Mf) rates varied
between 0 and 46%. Around 0.4% of the subjects with no or less than 8,000 Mf/ml were
FTS positive, while 22.2% of subjects with>8,000 Mf/ml were FTS positive. A L. loa Mf
density of>8,200 Mf/ml was determined as the cut point at which positive FTS results
should be excluded from the analysis. No FTS positive sample was positive for W. ban-
crofti antibodies as measured by two different point of care tests that use an antigen not
found in L. loa. Night blood examination of the FTS positive subjects also showed a high
prevalence of L. loa Mf with densities up to 12,710 Mf/ml, but no W. bancrofti Mf as con-
firmed by qPCR. Our results show that high L. loa Mf in day blood (> 8,200 Mf/ml) are a
predictor for FTS positivity and rapid antibody tests specific for W. bancrofti can be used
to confirm the absence of W. bancrofti. Our study provides a simple day blood-based algo-
rithm for LF mapping in loiasis areas. The results indicate that many districts that were
formerly classified as endemic for LF in Cameroon are non-endemic and do not require
mass drug administration for elimination of LF.
Introduction
Lymphatic filariasis (LF) is a neglected tropical disease that is targeted for elimination. A key
intervention strategy is mass drug administration (MDA) in all endemic areas with a microfi-
laria (Mf) or antigen prevalence of at least 1%. The Global Program to Eliminate Lymphatic
Filariasis (GPELF) has made substantial progress in a number of countries, but it lags behind
in others, especially in countries in western and central Africa [1, 2]. In order to tailor a cost-
effective and successful MDA program to country specific needs, accurate mapping of lym-
phatic filariasis distribution is a prerequisite. For most areas in sub-Saharan Africa, a combina-
tion of ivermectin with albendazole is used for MDA. However, in western and central Africa
where the filarial parasite Loa loa is highly co-endemic, twice yearly MDA with albendazole is
recommended [3]. The latter strategy has different dynamics for reduction of infection than
ivermectin combined with albendazole, but was recently shown to be effective for the local
elimination of LF [4].
There are little historical data on the distribution of LF in Cameroon. LF was assumed to be
widespread, especially in the northern part of the country, but confirmed parasitological data
were scarce [5]. A few studies report low prevalence of microfilaremia, not exceeding 1% [6,
7]. The presence of clinical disease, especially lymphedema, is considered to be a poor indica-
tor for LF in Cameroon, because podoconiosis associated lymphedema is common in some
areas [8–10]. In Africa, LF is exclusively caused be the filarial parasite Wuchereria bancrofti
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and detection of circulating W. bancrofti antigen in human blood using rapid diagnostic tests
has largely replaced microscopic detection and identification of microfilariae (Mf) in night
blood for mapping. While this powerful approach is facilitating the mapping of LF in many
areas, several recent studies have shown that this strategy is not reliable in areas highly
endemic for L. loa [11–13]. Individuals with high levels of L. loa Mf may contain sufficient
cross-reactive antigens in their blood that can be detected by the antibodies used in the diag-
nostic tests for W. bancrofti. Another confounder is that L. loa Mf are sometimes found in
moderate to high densities in night blood and could be easily misidentified by microscopy
with nocturnally periodic Mf of W. bancrofti [11]. Given these findings, LF mapping results
from L. loa endemic countries using mainly circulating filarial antigen tests must be inter-
preted with great caution [14].
The present study was designed to develop a simple and reliable algorithm for LF mapping
in areas co-endemic for L. loa. We collected day blood samples from about 5,000 subjects from
6 health districts located in different ecological zones and performed blood smears alongside
rapid filariasis antigen and antibody tests. We followed up the antigen positive subjects with
night blood collection and performed blood smears as well as qPCR to detect W. bancrofti and
L. loa DNA. The study answered the question whether positive antigen tests for W. bancrofti




In November and December of 2016 field data were collected from six health districts located
in five distinct areas in four geographical regions/bioecological zones (Fig 1, Table 1). The map
in Fig 1 was created using ArcGIS (ArcMap v10.5.1) software by Esri. ArcGIS and ArcMap are
the intellectual property of Esri and are used herein under license. The shape files were gener-
ated in house. A total of 50 communities were selected: 10 communities per managing health
district, with the exception of the Doume and Nguelemendouka health districts where 5 com-
munities from each were enrolled. The different bioecological zones represented varying levels
of endemicity of loaisis, circulating filarial antigen (ICT prevalence, potentially indicative of
W. bancrofti) and other filarial parasites (Onchocerca volvulus, Mansonella perstans, M. strepto-
cerca). The districts have varying histories of previous ivermectin treatment (Table 1). The
Yagoua health district in the Far-North region is situated in the shrub steppes and was consid-
ered endemic for LF more than 30 years ago [6], but with no loiasis based on RAPLOA data
[15]. The Nwa health district in the grassland savannah of the Northwest region showed low to
moderate ICT rates with varying levels of L. loa prevalence [13]. In the eastern region, the
Doume and Nguelemendouka health districts are part of the mosaic forest-savannah zone and
the ICT prevalence rates were relatively high with varying prevalence of L. loa based on
RAPLOA. In the east region, the Yokadouma and Lomie health districts were both located in
the dense humid rainforest and had relatively high ICT and L. loa prevalence rates compared
to the northern regions.
Study design and population
A cross-sectional community-based study design was used and from each of the 50 villages
100 residents were selected according to the guidelines for rapid mapping of bancroftian filari-
asis in Africa [16]. Villages were randomly selected from a list of villages provided by the health
center in the health district. If a village was inaccessible by car, a nearby village that was accessi-
ble was selected as replacement. Lomie health district managed some villages that were
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geographically located in the neighboring health district Abong Mbang but were difficult to
access from the Abong Mbang health center. Therefore, one village located in Abong Mbang,
but managed by Lomie was included (Fig 1).
Capillary blood samples were collected from male and female study participants aged 10
years or older and tested for Mf in day blood, circulating filarial antigen and anti-filarial anti-
bodies. Individuals that tested positive for circulating filarial antigen, or filarial antibodies
were re-examined at night using thick blood films and qPCR to detect W. bancrofti Mf. The
study profile is found in Fig 2
Ethical considerations
This study received approval from the Cameroon National Ethics Committee (No 2016/12/
835/L/CNERSH/SP) and administrative clearance from the Ministry of Public Health. Fur-
thermore, the Institutional Review Board of Washington University School of Medicine in
St. Louis approved the study. In the field, the objectives and procedures were explained to the
community leaders and all study participants. Parent or guardian of any child participant pro-
vided informed consent on the child’s behalf. Participation was voluntary and any participant
could withdraw at any moment during the study without obligations.
Clinical examination
Trained medical personnel recruited for this study examined all the participants for lymphoe-
dema. All individuals were examined for signs of the limb lymphedema and, if present, lymph-
edema severity was graded [17]. In addition, males were assessed for hydrocele.
Detection of circulating filarial antigen and anti-filarial IgG4 antibodies
Circulating filarial antigen was detected using filariasis test strips (FTS, Alere Scarborough,
Maine, USA). The FTS devices were stored at room temperature and carried to the field in
cooled polystyrene foam boxes. In each community, blood from each eligible participant was
tested directly in the field by FTS according to the manufacturer’s instructions. Briefly, 75μL of
heparinized finger-prick blood collected between 10am and 3pm was applied to the sample
application pad of the FTS. The reading of the results was performed strictly after 10 minutes.
A single test was performed for each participant.
Fig 1. Map of Cameroon. This map shows each village location within the six managing health districts enrolled in the study. Lomie health district
managed a village for the neighboring Abong Mbang health district. This map was created using ArcGIS (ArcMap v10.5.1) software by Esri.
https://doi.org/10.1371/journal.pntd.0007192.g001
Table 1. Ecological properties and history of community-directed treatment with ivermectin (CDTi) of communities/villages screened for the presence of lymphatic




Yagoua Nwa Nguelemendouga Doume´ Yokadouma Lomie´
Community number 1 2 3 4 5 6
Region Far Northern Northwestern Eastern (central) Eastern (central) Eastern Eastern (south)








RAPLOA classification Non-endemic High endemicity High endemicity High endemicity High endemicity High endemicity




No CDTi No CDTi No CDTi No CDTi
https://doi.org/10.1371/journal.pntd.0007192.t001
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Fig 2. Study profile. Study profile showing the main study results. The rapid point of care tests FTS, Wb123 (monoplex)
and Wb123 (biplex) sometimes produced indeterminate results. �positive by Wb123 monoplex or biplex test.
https://doi.org/10.1371/journal.pntd.0007192.g002
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For the detection of anti-filarial IgG4 antibodies, two different rapid diagnostic tests, a
monoplex and a biplex coupled with the Ov16 antigen reactive with O. volvulus antibodies
were used according to the recommendation of the manufacturer (Standard Diagnostics, Yon-
gin, South Korea) [18]. Both tests were performed in parallel with the FTS test on capillary day
blood samples.
Parasitological examination
Diurnal blood collections were performed between 10am-3pm while nocturnal collections
were done between 10pm-12am. For diurnal collections, 50μL non-heparinized finger-prick
blood was used to prepare thick blood films (TBF) for the detection of Mf. At night, two sepa-
rate non-heparinized finger-prick blood samples were collected: one 50 μL sample was used to
prepare a TBF and the other 60 μL sample was used to generate preserved dried blood spots on
filter paper (TropBio, Townsville, Australia). The TBF was stained with 10% Giemsa using
standard procedures [6] and examined using a light microscope at 100-fold magnification for
any blood dwelling Mf. Mf were identified by species, quantified and recorded. To aid proper
identification of Mf, slides were sometimes also examined at 400- or 1,000-fold magnification.
Detection of filarial DNA in night blood by qPCR
Night blood was collected on filter paper from 61 subjects. DNA extractions were done from
60 μl of night blood, which was evenly distributed on filter paper disks, 10 μl on each “ear”
(TropBio, Townsville, Australia). Briefly, all six disks were collected in a 1.5 ml tube and sub-
merged in 200 μl of 1X PBS and 20 μl proteinase K. After incubation at 56˚C for an hour the
DNeasy blood and tissue kit (Qiagen, Hilden, Germany) was used to perform the remaining
steps of the protocol. The final elution was performed in 100 μl DEPC water. Using TaqMan
Master Mix (Applied Biosystems, Foster City, CA, USA) as reaction chemistry, samples were
tested in two separate qPCRs for of W. bancrofti and L. Loa. For the detection of W. bancrofti
the “long DNA repeat” (LDR) was used as a target with primers and probes as described previ-
ously [19]. The primers and probes used for the L. loa qPCR were described by Fink and co-
workers [20]. All oligonucleotides were obtained by Integrated DNA Technologies (Skokie, IL,
USA). The qPCR was performed at the University of Buea using the CFX Biorad thermocycler
with a 10 μl/well set up. All reactions were carried out in duplicates and non-template control
and a known positive sample were included in each run. Samples were considered to be posi-
tive if the cycle threshold value was < 40. For quality control, all samples were re-tested at
Washington University School of Medicine in St. Louis using a Fast TaqMan Master Mix and
a Quantstudio 6 thermocycler (Applied Biosystems).
Data collection and statistical analysis
Demographic information was collected using the EpiInfo for Mobile Devices App (Centers
for Disease Control and Prevention, Atlanta, GA) on a Samsung Galaxy tablet. This informa-
tion was linked for each study participant to a unique barcode identifier. This barcode was also
attached to the laboratory data collection forms and used to track study results. Data were
transmitted via cloud to Washington University School of Medicine and imported to SPSS
v20.0.0 (Armonk, NY: IBM Corp) for analysis. The geometric mean intensity (GMI) of Mf
counts was calculated as antilog (∑log(x+1) /n), with "x" being the number of Mf per mL of
blood in Mf positive individuals and "n" the number of Mf positive individuals examined. To
estimate prevalence, we used a generalized linear mixed model (PROC GLIMMIX [SAS, 9.4])
with a logit linking function and a random effect to account for correlation among villages
within a district. Additionally, we used a classification-tree analysis (PROC HPSPLIT [SAS,
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9.4]) to determine the Mf density cut point that best splits the FTS outcome into groups, and
estimated the prevalence for the groups below and above the cut point.
Results
Microfilariae in day blood
Only Mf of L.loa and M. perstans were detected in day blood (Table 2). Five of the six study
health districts were found to be endemic for loiasis (Mf prevalence�1%) with the highest
prevalence of L. loa Mf in the central-east region (Doume & Nguelemendouga) ranging from
19 to 87%, and the lowest in the north-west region (Nwa) ranging from 2 to 18% (Supplemen-
tary File 1). The savanna region in the far north (Yagoua) was not endemic for L. loa with only
a single Mf positive subject. The highest geometric mean L. loa Mf density in infected individ-
uals was observed in the south-east (Yokadouma) region with 957.4 Mf/ml and the maximum
Mf count in a subject with 164,210 Mf/ml. In this area the geometric mean L. loa Mf density
varied between the villages from 241 Mf/ml to 3,192 Mf/ml.
M. perstans was co-endemic in four of the six regions, but prevalence rates and density of
infection was much lower (Table 2). The highest prevalence of M. perstans was found in the
central-east region of Doume´ with prevalence of 43.9% in one village. The highest geometric
mean density in infected subjects was 164.6 Mf/ml also in Doume. In this health district, the
person with the highest count of M. perstans Mf was observed with 24,080 Mf/ml. The small,
non-sheathed Mf of M. perstans were easily differentiated from the larger, sheathed Mf of L.
loa. No Mf of other filarial parasites (W. bancrofti or O. volvulus) that usually do not circulate
in day blood were observed.
Circulating filarial antigen and filarial-specific antibodies
Circulating filarial antigen measured by the FTS assay as an indicator for W. bancrofti infec-
tion was detected in all six study areas and the overall prevalence was 1.1% (Table 3). However,
the FTS prevalence rates in three areas were below 1%, while in the Nguelemendouga, Doume,
and Yokadouma health districts areas rates were between 1.6 and 2.2%. In these areas, 16
(80%) of the 20 villages had rates of 1% or above (Supplemental File 1). The highest rates of
positive FTS test results were detected in 2 villages of the Yokadouma area with 5.5 and 4.2%.
Overall 14% of the study villages accounted for 50% of the positive FTS results. These results
demonstrate that subjects with positive FTS results were not evenly distributed in the 50
study villages, but concentrated in the southern rainforests, where high L. loa Mf rates were
observed. Overall, of the 52 FTS positive subjects, 38 (73.1%) were also positive for L. loa Mf
by thick day blood smear (Table 2). Among these 38 FTS and L. loa Mf positive individuals, 24
(63%) had L. loa Mf densities of 8,200 Mf/ml or above (Fig 2).
Table 2. Prevalence (with 95% confidence interval CI), geometric mean density (with standard deviation SD) of infected individuals, and maximum count of micro-
filaria (Mf) of L. loa and M. perstans in day blood in 6 health districts in Cameroon.
Health District N L. loa M. perstans
Mf % (95% CI) Mean Mf/ml (SD) Max Mf/ml Mf % (95% CI) Mean Mf/ml (SD) Max Mf/ml
Yagoua 1000 0.1 (0.0, 0.8) 30.00 30 0 0 0
Nwa 1000 7.0 (4.5, 10.8) 621.91 (7.3) 23320 0 0 0
Nguelemendouga 484 40.6 (22.8, 61.2 524.6 (8.5) 145060 1.4 (0.2, 8.6) 80.3 (6.8) 2760
Doume´ 501 47.2 (22.7, 73.8) 572.3 (9.8) 101730 16.1 (6.1, 35.9) 168.4 (6.9) 24080
Yokadouma 1016 28.9 (24.4, 33.9) 957.4 (10.9) 164210 1.8 (1.0, 3.2) 47.4 (6.0) 3910
Lomie´ 1000 25.6 (18.1, 34.8) 146.3 (7.3) 28610 6.2 (3.1, 12.2) 47.5 (3.6) 2870
Total 5001 12.8 (8.1, 19.7) 462.1 (10.0) 164210 1.4 (0.8, 2.5) 87.5 (6.0) 24080
https://doi.org/10.1371/journal.pntd.0007192.t002
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Specific antibodies reactive with the recombinant W. bancrofti antigen Wb123 were
assessed by two different Point-of-Care (PoC) diagnostic tests: The Wb123 monoplex test
detects antibodies reactive with the Wb123 antigen alone and the Wb123/Ov16 biplex test
detects antibodies reactive with Wb123 and with the O.volvulus specific antigen Ov16. In total,
22 subjects were positive with any of these two Wb123 tests, but there was a considerable dif-
ference between both tests. The Wb123 monoplex detected antibodies reactive with Wb123 in
10 subjects while the Wb123 biplex detected antibodies in 18 subjects. Of the 18 positive biplex
individuals, 8 of them were also positive by the monoplex test. The distribution of positive
Wb123 results was relatively even among the study areas and villages. Apart from one village
that had two positive individuals, all other 49 villages had 0 or 1 subject with a positive Wb123
result. None of the subjects with a positive FTS test result were positive with any of the Wb123
antibody tests.
Since the biplex test also measures antibodies reactive with Ov16, data on the distribution
of onchocerciasis were collected. The rate of positive Ov16 tests was highly variable among the
6 study districts (Table 4). Yagoua, Nguelemendouga, Doume, and Yokadoume each had a
positive rate of 1% or less. In contrast, Lomie had 7.6% positive tests and Nwa had 28.8% posi-
tive Ov16 tests. In the latter area, the rate of positive tests varied within the villages between
15.2 and 50%.
Microfilariae and filarial DNA in night blood
Subjects with positive FTS or PoC Wb123 test (monoplex or biplex) results were followed up
for night blood collections to screen for Mf and DNA of W. bancrofti. In total, 46 night blood
Table 3. Frequency of positive filarial antigen tests (FTS) by L. loa microfilaria (Mf) density in the 6 study health districts in Cameroon.
Yagoua Nwa Nguelemendouga Doume´ Yokadouma Lomie´ Total
Mf/mL Na FTS+ N FTS+ N FTS+ N FTS+ N FTS+ N FTS+ N FTS+ (%)
0 999 5 916 5 283 1 262 0 718 1 714 2 3,892 14 (0.3)
1–7,999 1 0 66 0 176 1 194 4 227 2 251 0 915 7 (0.8)
8,000–30,000 0 0 10 2 14 6 25 5 48 10 11 1 108 24 (22.2)
>30,000 0 0 0 0 6 0 5 2 19 5 0 0 30 7 (23.3)
Total 1,000 5 992 7 479 8 486 11 1,012 18 976 3 4,945 52 (1.1)
a- Samples that did produce an indeterminate FTS result are not included in N
https://doi.org/10.1371/journal.pntd.0007192.t003
Table 4. Summary of the antigen (FTS) and antibody (Wb123 monoplex, Wb123/Ov16 biplex) serology results (95% confidence interval, CI) using in the 6 study
areas in Cameroon.
Na FTS % (95% CI)b Monoplex
Wb123% (95% CI)
Biplex
Health District Wb123% (95% CI) Ov16% (95% CI)
Yagoua 1000 0.3 (0.1, 1.4) 0 0.2 (0.0, 0.8) 0.1 (0.0, 0.8)
Nwa 1000 0.7 (0.3, 1.5) 0.1 (0.0, 0.8) 0.4 (0.0, 0.9) 28.2 (22.0, 35.4)
Nguelemendouga 484 1.7 (0.9, 3.2) 0.4 (0.1, 1.4) 0.4 (0.1, 1.4) 0.6 (0.2, 2.4)
Doume´ 501 2.3 (1.2, 4.1) 0.4 (0.1, 1.6) 0.3 (0.0, 2.7) 0.8 (0.2, 3.6)
Yokadouma 1016 1.6 (0.8, 3.2) 0.2 (0.0, 0.8) 0.4 (0.2, 0.9) 0.1 (0.0, 0.7)
Lomie´ 1000 0.3 (0.1, 0.9) 0.3 (0.1, 0.9) 0.4 (0.2, 0.9) 7.4 (5.2, 10.3)
Total 5001 1.0 (0.7, 1.4) 0.2 (0.1, 0.4) 0.4 (0.2, 0.5) 2.0 (1.0, 3.7)
a Number of subjects that provided a specimen.
b No individual positive by FTS was also positive by Wb123
https://doi.org/10.1371/journal.pntd.0007192.t004
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samples of FTS positive subjects were screened and none of them were positive for W. ban-
crofti either by microscopy or by qPCR (Table 5). In contrast, 32 of these night blood samples
were positive for Mf of L. loa by microscopy and 28 were positive for L. loa by qPCR. Similarly,
among the 15 Wb123 positive subjects who provided a night blood sample, none were positive
for W. bancrofti by either assay (Table 6).
The only Mf found in these 61 night blood samples where those of L. loa. In total 36 (60%)
of these samples were positive for L.loa Mf, and the highest density of L.loa Mf in night blood
was 9,180 Mf/ml. The densities of L. loa Mf in night blood were usually much lower compared
to the densities of matching day blood samples (Fig 3).
Strategy for LF mapping
Our data show that the FTS antigen test is highly specific in areas not endemic for loiasis, spe-
cifically Yagoua, where the L. loa Mf prevalence is less than 1%. In areas with higher loiasis
prevalence, the PoC Wb123 tests can be used as confirmatory test, and thus far, it appears that
biplex Wb123 test may have a higher sensitivity. If reliable rapid Wb123 diagnostic tests for
confirmation are not available, examination of a thick blood smear of day blood collected from
FTS positive individuals can be used as indicator for potential cross-reactivity with L.loa anti-
gens. In order to determine the L. loa Mf density threshold at which positive FTS results should
be excluded analysis and considered as indeterminate we performed a classification-tree analy-
sis. An Mf density of 8,200 Mf/ml or less was determined as the cut point. At this density 0.4%
(95% CI 0.3, 0.7) where FTS positive, while at higher densities (>8,200 Mf/ml) 22.5% (95% CI
Table 5. qPCR results of FTS positives who were followed up for night blood collection.
Health District FTS+ testeda Loa Mf + (%) Max Mf/ml Wb qPCR+ L. loa qPCR+ (%)b
Yagoua 5 0 0 0 0
Nwa 7 2 (28.6) 22,080 0 2 (100)
Nguelemendouga 6 6 (100) 23,100 0 5 (83.3)
Doume´ 10 10 (100) 50,350 0 8 (80.0)
Yokadouma 15 14 (93.3) 164,210 0 12 (85.7)
Lomie´ 3 1 (33.3) 20,470 0 1 (100)
Total 46 33 (71.7) 164,210 0 28 (84.8)
a Only FTS positive individuals that provided a night blood samples were subjected to qPCR
b Percentage is derived from the number of Mf+ samples
https://doi.org/10.1371/journal.pntd.0007192.t005
Table 6. qPCR results of Wb123 positive subjects who were followed up for night blood collection.
Health District Wb123+ testeda Loa Mf + (%)b Wb qPCR+ L. loa qPCR+ (%)b
Yagoua 0 0 0 0
Nwa 4 0 0 0
Nguelemendouga 2 2 (100) 0 0
Doume´ 3 0 (0) 0 1 (33.3)
Yokadouma 2 0 (0) 0 0
Lomie´ 4 1 (25.0) 0 1 (25.0)
Total 15 3 0 2
a Positive by either monoplex or biplex assays
b Percentage is derived by number of Wb123+ samples
https://doi.org/10.1371/journal.pntd.0007192.t006
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16.8, 29.4) were FTS positive. Therefore, FTS results of subjects with more than 8,200 L. loa Mf
per ml day blood during LF mapping should be considered as indeterminate. This adjustment
would reduce in our case the sample size by only 0.6% and the overall rate of positive FTS
results would drop by more than half from 1.0% to 0.4%. Furthermore, none of the individual
health districts (implementation units) would have had an FTS rate of�1% and would require
MDA to eliminate LF.
Discussion
The present study showed that high densities of L. loa Mf confounds mapping of LF using FTS
for the detection of circulating filarial antigen. This finding is in line with previous reports and
indicates that tests for circulating filarial antigens alone cannot unambiguously detect LF
endemicity is areas highly endemic for loiasis [11–13, 21]. These observations have profound
implications for the classification of Cameroon as LF endemic country.
Our results of day blood examination showed that 5 of the 6 health district areas were
endemic for L. loa and 4 of the 6 areas were endemic for M. perstans (Table 2). These results
were expected and agree with previous reports [15, 22]. Although L. loa Mf densities were
Fig 3. Comparison of microfilaria (Mf) densities in day and in night blood. Data were determined by thick blood smear of
capillary blood. Samples were collected from subjects who were either circulating antigen (FTS) or antibody (Wb123) test positive
during the initial screening.
https://doi.org/10.1371/journal.pntd.0007192.g003
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usually higher in day blood, some subjects had also relatively high Mf densities of>1,000 Mf/
ml in night blood (Fig 2). This observation was reported previously but is still not widely rec-
ognized [11]. Furthermore, we found no evidence for the presence of W. bancrofti Mf by
microscopy or qPCR in night blood (Tables 5 and 6). Therefore, it must be stressed that in loia-
sis endemic regions large, sheathed Mf in night blood may be due to L. loa and not due to W.
bancrofti infection.
The rapid PoC Wb 123 monoplex and biplex tests are unlikely to cross-react with antibod-
ies to L. loa or M. perstans and may be suitable as a confirmatory test for the FTS antigen detec-
tion. However, the detailed sensitivity and specificity of these tests in the field are not well
established and the agreement was relatively poor. Therefore, we prefer to use L. loa Mf densi-
ties in day blood to validate FTS results. If FTS results of individuals with>8,200 L. loa Mf/ml
are considered to be indeterminate and excluded from the analysis the problem of cross-reac-
tivity is greatly reduced. Since usually only a small percentage of FTS tests are positive, deter-
mination of Mf density in day blood for these subjects should not be a logistical or technical
problem. This can be easily done directly in the field by blood smear or if available by Loa-
Scope technology [23].
The use of the Wb123/Ov16 biplex test also provided information about the distribution of
onchocerciasis. A high rate of positive Ov16 results in the population does not necessarily
mean that an area is still endemic for onchocerciasis and that transmission of O. volvulus is
ongoing. However, a very low rate of positive Ov16 results (with the assumption of a decent
sensitivity of the test device) indicates that the area is not highly endemic for onchocerciasis.
Our results agree well with the known distribution of onchocerciasis in Cameroon with a
major focus in the west and a smaller in the south [24].
Published information on the current or historical distribution of LF in Cameroon is very
limited. The country has a population of about 23 million residents and few of them have been
properly tested for LF. In a study performed from 2009 to 2010, 10,943 individuals from 8
regions were tested for circulating filarial antigen by ICT and positivity rates ranged from 1 to
8% [14]. In that study, positive tests were not confirmed by other tools to diagnose W. ban-
crofti infection and positive tests could be due solely to cross-reactivity with L. loa antigens. In
a second survey, included in that study, Nana-Djeunga and co-workers tested more than
26,000 individuals from these regions for Mf in night blood and found zero Mf in 4 regions
and less than 0.5% in the other regions [14]. Therefore, these mapping data do not support LF
endemicity (infection prevalence� 1%) in Cameroon.
A more recent study reported evidence of interruption of LF transmission in a few evalua-
tion units in the North and Far North region [25]. Given the poor quality of mapping data, it is
not clear whether these areas were endemic for LF before the start of MDA with ivermectin
plus albendazole and whether MDA for LF elimination was justified. However, parts of these
regions are endemic for onchocerciasis and received CDTi prior to MDA with ivermectin plus
albendazole [26]. A recent literature review highlighted the very limited information available
on LF prevalence in areas endemic for loiasis and found increasing evidence for low or no W.
bancrofti prevalence in high risk L. loa areas [27]. Our study provides further evidence and
proposes a solution for reliable verification mapping of LF in loiasis areas. Without any further
LF specific intervention, it may be possible now to declare the entire country of Cameroon or
at least large parts as non-endemic for LF.
In the present study we developed an algorithm to increase specificity of antigen testing
using FTS for detection of W. bancrofti infection in areas endemic for L. loa by excluding FTS
results from subjects with >8,200 L. loa Mf per ml. This threshold would also significantly
reduce the number of FTS positive results because of cross-reactivity with L. loa from another
study performed in Cameroon [12]. However, additional data would be helpful to determine
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the robustness of this threshold. Investing in proper mapping of LF in L. loa endemic areas
may not only help to avoid unnecessary MDA for LF elimination, it may also help to shrink
the map of LF distribution. It is possible that in Central Africa where loiasis is endemic, the
GPELF is much closer to its goal than assumed previously.
Conclusion
This study confirmed that high loads of L. loa Mf confounds LF mapping using circulating
filarial antigen tests. Validation of FTS positive subjects using Wb123 tests or better tests for
high L. loa Mf loads can help to circumvent the problem of cross-reactivity of antigen tests
with L. loa. All FTS positive samples with high L. loa Mf loads (>8,200 Mf/ml) should be con-
sidered as indeterminate FTS results and should be excluded from the analysis.
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